This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

2015: Conversations in Oncology in Mexico

Recent talks from Boehringer Ingelheim standalone meetings

The Conversations in Oncology in Mexico was the first of its kind to be held in Latin America and brought together 170 doctors from across Latin and South America in Cancun, Mexico, in October 2015. A unique ‘joint venture’ between the well-respected national “Debates in Cancer” (already in its 5th year) and the Boehringer Ingelheim “Conversations in Oncology” initiative, this event gave the audience the chance to attend both plenary sessions and smaller workshops, discussing case studies and scientific questions.


To view slides from the various presentation, simply click on your file of choice below.



Lung Cancer: Molecular Biology 2015

Next-Generation Sequencing/Biomarkers: Advanced Technology

State of the Art in Urothelial Cancers

Management of Brain Metastases and Oligometastases in Non–Small Cell Lung Cancer (NSCLC)

Novel Advances in the Management of Squamous Cell Carcinoma of the Head and Neck

Challenges in the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

Impact of Overall Survival in Advanced NSCLC EGFR+

Best Practices in Pathology: Are We There Yet?

Treatment of Wild Type Non-Small Cell Lung Cancer: 2015

Immunotherapeutic Approaches in the Treatment of NSCLC

State of the Art Colorectal Cancer (CRC)

Targeting Angiogenesis in NSCLC

The Story of BIBF1120 – Nintedanib*–Vargatef®

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.